1. Home
  2. BEAM vs GNL Comparison

BEAM vs GNL Comparison

Compare BEAM & GNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$27.06

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Logo Global Net Lease Inc.

GNL

Global Net Lease Inc.

HOLD

Current Price

$8.80

Market Cap

1.9B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
GNL
Founded
2017
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
1.9B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
BEAM
GNL
Price
$27.06
$8.80
Analyst Decision
Strong Buy
Buy
Analyst Count
12
2
Target Price
$48.09
$9.00
AVG Volume (30 Days)
1.5M
1.8M
Earning Date
02-24-2026
11-05-2025
Dividend Yield
N/A
8.62%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$55,701,000.00
$751,333,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$26.52
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
17.63
52 Week Low
$13.53
$6.51
52 Week High
$35.25
$8.85

Technical Indicators

Market Signals
Indicator
BEAM
GNL
Relative Strength Index (RSI) 53.35 69.17
Support Level $26.71 $8.20
Resistance Level $28.00 $8.62
Average True Range (ATR) 1.23 0.17
MACD -0.08 0.02
Stochastic Oscillator 47.95 90.84

Price Performance

Historical Comparison
BEAM
GNL

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About GNL Global Net Lease Inc.

Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.

Share on Social Networks: